华森制药：HSN002066C1片药物临床试验获批准

Core Viewpoint - Huason Pharmaceutical (002907.SZ) announced that its subsidiary, Chongqing Huason Yino Biotechnology Co., Ltd. (referred to as "Huason Yino"), has received the Clinical Trial Approval Notice from the National Medical Products Administration for the HSN002066C1 tablet in two specifications [1] Group 1 - HSN002066C1 tablet (with free base HSN002B015) is a selective small molecule inhibitor of poly(ADP-ribose) polymerase 7 (PARP7) developed independently by Huason Yino, with full ownership of intellectual property rights [1] - The clinical application of HSN002066C1 is intended for the treatment of patients with advanced malignant solid tumors [1] - HSN002066C1 is characterized as a potent and highly selective PARP7 inhibitor, showing significant tumor suppression activity in various tumor models when administered alone or in combination [1]